News

News
VitaDX
4th round of financing for VitaDX
21 September 2020 -

VitaDX completes a €3M financing round with its historical investors GO CAPITAL, ODYSSEE Venture and FFBB Management and its financial partners…

VisioCyt
CE marking of the VisioCyt® solution
11 February 2020 -

VitaDX is very proud to announce the CE marking of its first software solution dedicated to bladder cancer diagnosis: VisioCyt®.

VitaDX, Go Capital, Odyssee Venture et Auriga
VitaDX raises €4 million from GO CAPITAL, AURIGA Partners, ODYSSEE Venture and FFBB Management
9 July 2019 -

This fundraising will allow VitaDX to finalize the development and ensure the commercial deployment of its first early bladder cancer detection…

UC3
UC3: VitaDX, Cerballiance Finistère and the COSS laboratory are collaborating within the framework of the "Collaborative innovation at the crossroads of different sectors" initiative.
14 May 2019 -

The Characterisation of Urothelial Cancer Cells "UC3" project funded by the Brittany region, Rennes Métropole and the ERDF aims to deepen our…

La Tribune
”Paroles d’Experts” show by La Tribune
16 July 2018 -

Allan Rodriguez (CEO and co-founder of VitaDX) and Pascal Eschwège (Professor of Urology at the University Hospital of Nancy and co-founder of…

DeepTech4Good Paris
DeepTech4Good Paris
12 July 2018 -

VitaDX is very happy to be a Health & Wellness Laureate at DeepTech4Good !

Realize
REALIZE AstraZeneca
11 July 2018 -

VitaDX is very pleased to be part of the 5 Therapeutic Innovation Startups selected by AstraZeneca to be part of the support program REALIZE!

Le MAG numérique
Against cancer VitaDX invests 5 years of efforts.
31 May 2018 -

Five years of efforts to transform a patented technology into an industrialised solution, tested and certified.

Le Télégramme
Artificial intelligence. Healthcare and patients have everything to gain from the digital era – Le Télégramme
15 May 2018 -

VitaDX citée dans Le Télégramme à l'occasion de la journée Numérique & Santé.